Sucampo Pharma Gets UK Approval for Amitiza

Sucampo Pharmaceuticals, Inc. (“Sucampo”)

today announced that it has received approval from the Medicines and Healthcare products Regulatory Agency for AMITIZA® (lubiprostone) 24 mcg twice daily for the treatment of chronic idiopathic constipation (CIC) and associated symptoms in adults, when response to diet and other non-pharmacological measures (e.g., educational measures, physical activity) are inappropriate.